A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.

Terese Monette O AquinoKarla Angela C LuchangcoElizabeth V SanchezVermen M Verallo-Rowell

Published in: International journal of dermatology (2020)

Our results suggest that short-term use of topical gabapentin may significantly decrease CKD-AP severity after 2 weeks with no reported acute adverse events.

Keyphrases

chronic kidney disease
end stage renal disease
neuropathic pain
liver failure
wound healing
respiratory failure
drug delivery
transcription factor
drug induced
spinal cord injury
gestational age
atopic dermatitis
hepatitis b virus
intensive care unit